CMC4抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08528(CMC4 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P08528(CMC4 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of CMC4 Antibody**

The CMC4 antibody is a monoclonal antibody developed to target specific cell surface antigens, often associated with cancer progression. It was designed to recognize epitopes expressed on tumor cells, particularly in malignancies such as colorectal cancer, breast cancer, or other solid tumors. CMC4 likely functions by binding to these antigens, blocking downstream signaling pathways critical for tumor survival, proliferation, or metastasis. Its development stemmed from efforts to identify biomarkers or therapeutic targets with high specificity for cancer cells while minimizing off-target effects on healthy tissues.

Structurally, CMC4 is an IgG-class antibody engineered for enhanced affinity and stability. Preclinical studies suggest it may induce antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), leveraging the immune system to eliminate targeted cells. Research has also explored its potential in diagnostic imaging or as a drug conjugate for targeted therapy delivery.

While detailed clinical data remain limited, CMC4 represents a candidate for precision oncology, with ongoing investigations into its efficacy, safety, and compatibility with combination therapies like chemotherapy or immune checkpoint inhibitors. Further validation is required to establish its therapeutic utility and optimize dosing regimens.